First Manhattan
AEGR

First Manhattan’s Aegerion Pharmaceuticals AEGR Stock Holding History

First Manhattan’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-263,068
Closed -$18.7M – 1499
2013
Q4 		$18.7M Sell
263,068
-48,200
-15% -$3.69M 0.12% 125
2013
Q3 		$26.7M Sell
311,268
-61,837
-17% -$5.24M 0.19% 93
2013
Q2 		$28.8M Buy
+373,105
New +$19.8M 0.2% 88

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

First Manhattan's AEGR Position: Q1 2014 in Review

First Manhattan sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 263,068 shares — an estimated $18.7M sold.

First Manhattan first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $28.8M in Q2 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • First Manhattan reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • First Manhattan sold 263,068 Aegerion Pharmaceuticals shares in Q1 2014, an estimated $18.7M.
  • First Manhattan first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • First Manhattan's Aegerion Pharmaceuticals position peaked at $28.8M in Q2 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on First Manhattan's 13F filing for Q1 2014, filed 16 May 2014.